Add to ORKGPopulation-based testing for BRCA1/2 mutations detects the high proportion of carriers not identified by cancer family history (FH)-based testing. We compared the cost-effectiveness of population-based BRCA testing with the standard FH-based approach in Ashkenazi Jewish (AJ) women
Background: The cost-effectiveness of population-based panel testing for high- and moderate-penetran...
r t ic le This is an Open Access article distributed under the terms of the Creative Commons Attribu...
Background: Identification of BRCA mutation carriers among patients with breast cancer (BC) involves...
BACKGROUND: Population-based BRCA1/BRCA2 founder-mutation testing has been demonstrated as cost effe...
BACKGROUND: Population-based BRCA1/BRCA2 testing has been found to be cost-effective compared with f...
Identifying carriers of pathogenic BRCA1/BRCA2 variants reduces cancer morbidity and mortality throu...
BACKGROUND: Population-based BRCA1/BRCA2 founder-mutation testing has been demonstrated as cost effe...
BACKGROUND: Population-based BRCA1/BRCA2 testing has been found to be cost-effective compared with f...
Population based BRCA1/BRCA2 testing has been found to be cost-effective compared to family-history ...
BACKGROUND: Population based BRCA1/BRCA2 testing has been found to be cost-effective compared to fam...
The study was funded by The Eve Appeal charity. The study is supported by researchers at the Barts C...
Clinical criteria/Family history-based BRCA testing misses a large proportion of BRCA carriers who c...
Clinical criteria/Family history-based BRCA testing misses a large proportion of BRCA carriers who c...
This study was funded by ‘The Eve Appeal’ charity. The funding body (The Eve Appeal charity) had no...
Acknowledgments We are grateful to Melissa Southey (Monash University, Australia) for her support of...
Background: The cost-effectiveness of population-based panel testing for high- and moderate-penetran...
r t ic le This is an Open Access article distributed under the terms of the Creative Commons Attribu...
Background: Identification of BRCA mutation carriers among patients with breast cancer (BC) involves...
BACKGROUND: Population-based BRCA1/BRCA2 founder-mutation testing has been demonstrated as cost effe...
BACKGROUND: Population-based BRCA1/BRCA2 testing has been found to be cost-effective compared with f...
Identifying carriers of pathogenic BRCA1/BRCA2 variants reduces cancer morbidity and mortality throu...
BACKGROUND: Population-based BRCA1/BRCA2 founder-mutation testing has been demonstrated as cost effe...
BACKGROUND: Population-based BRCA1/BRCA2 testing has been found to be cost-effective compared with f...
Population based BRCA1/BRCA2 testing has been found to be cost-effective compared to family-history ...
BACKGROUND: Population based BRCA1/BRCA2 testing has been found to be cost-effective compared to fam...
The study was funded by The Eve Appeal charity. The study is supported by researchers at the Barts C...
Clinical criteria/Family history-based BRCA testing misses a large proportion of BRCA carriers who c...
Clinical criteria/Family history-based BRCA testing misses a large proportion of BRCA carriers who c...
This study was funded by ‘The Eve Appeal’ charity. The funding body (The Eve Appeal charity) had no...
Acknowledgments We are grateful to Melissa Southey (Monash University, Australia) for her support of...
Background: The cost-effectiveness of population-based panel testing for high- and moderate-penetran...
r t ic le This is an Open Access article distributed under the terms of the Creative Commons Attribu...
Background: Identification of BRCA mutation carriers among patients with breast cancer (BC) involves...